Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment.

Antifungal Agents / pharmacology Drug Carriers / therapeutic use Drug Delivery Systems / methods Eye Infections, Fungal / drug therapy Humans Keratitis / drug therapy Particle Size Permeability Poloxamer Polymers Rotaxanes / therapeutic use Tolnaftate / therapeutic use
Aspergillus niger Keratitis Tolnaftate ocular permeability susceptibility

Journal

Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471

Informations de publication

Date de publication:
Dec 2022
Historique:
entrez: 11 7 2022
pubmed: 12 7 2022
medline: 14 7 2022
Statut: ppublish

Résumé

Fungal keratitis (FK) is a devastating ocular disease that can cause corneal opacity and blindness if not treated effectively. Tolnaftate (TOL) is a selective fungicidal drug against Aspergillus spp. which are among the most common causes of mycotic keratitis. TOL is lipophilic drug with low water solubility and permeation which act as obstacles for its clinical ocular efficacy. Hence, this study aimed to statistically optimize a novel polymeric pseudorotaxanes (PSRs) containing TOL for enhancing its ocular permeability and antifungal effect. For achieving this goal, a full 3

Identifiants

DOI: 10.1080/10717544.2022.2094499 PMID: 35815689 PMC: PMC9278446
pubmed: 35815689
doi: 10.1080/10717544.2022.2094499
pmc: PMC9278446
doi:

Substances chimiques

Antifungal Agents 0
Drug Carriers 0
Polymers 0
Rotaxanes 0
Tolnaftate 06KB629TKV
Poloxamer 106392-12-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2162-2176

Références

Indian J Exp Biol. 2001 Jan;39(1):11-24
pubmed: 11349520
Rev Inst Med Trop Sao Paulo. 2015 Sep;57 Suppl 19:57-64
pubmed: 26465371
AAPS PharmSciTech. 2009;10(3):858-63
pubmed: 19562489
Drug Dev Ind Pharm. 2016 Sep;42(9):1446-54
pubmed: 26765786
Eur J Pharm Sci. 2017 Nov 15;109:288-296
pubmed: 28823856
Mol Pharm. 2018 Feb 5;15(2):571-584
pubmed: 29313693
Int J Pharm. 2015 Aug 15;492(1-2):28-39
pubmed: 26151106
J Drug Target. 2014 Aug;22(7):576-83
pubmed: 25012065
Biomed Res Int. 2015;2015:198268
pubmed: 26582104
Drug Deliv. 2021 Dec;28(1):77-86
pubmed: 33342315
Int J Pharm. 2016 Nov 20;513(1-2):688-696
pubmed: 27717916
Drug Deliv. 2018 Nov;25(1):1706-1717
pubmed: 30442039
Drug Deliv. 2016 Nov;23(9):3681-3695
pubmed: 27648847
Drug Deliv. 2016 Sep;23(7):2115-2123
pubmed: 25080226
Clin Ophthalmol. 2019 Dec 24;13:2573-2582
pubmed: 31920280
Nepal J Epidemiol. 2017 Jun 30;7(2):685-693
pubmed: 29181230
J Liposome Res. 2013 Sep;23(3):203-10
pubmed: 23607316
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
Colloids Surf B Biointerfaces. 2015 Apr 1;128:322-330
pubmed: 25707750
Drug Deliv. 2018 Nov;25(1):484-492
pubmed: 29411650
Int J Pharm. 2010 Sep 15;397(1-2):164-72
pubmed: 20599487
Molecules. 2014 Sep 09;19(9):14066-79
pubmed: 25207713
J Phys Chem B. 2009 Mar 5;113(9):2773-82
pubmed: 19708112
Drug Deliv. 2019 Dec;26(1):158-167
pubmed: 30822157
Int J Pharm. 2011 Jul 15;413(1-2):202-10
pubmed: 21540093
J Young Pharm. 2012 Oct;4(4):220-7
pubmed: 23493156
Drug Deliv. 2018 Nov;25(1):815-826
pubmed: 29557244
J Ocul Pharmacol Ther. 2008 Oct;24(5):481-93
pubmed: 18788998
Acta Ophthalmol. 2015 Feb;93(1):54-8
pubmed: 24836583
Nanomaterials (Basel). 2021 Jan 12;11(1):
pubmed: 33445545
J Liposome Res. 2017 Jun;27(2):118-129
pubmed: 27079800
Int J Pharm. 2018 Dec 20;553(1-2):386-397
pubmed: 30393167
Drug Deliv. 2019 Dec;26(1):509-521
pubmed: 31090464
Drug Deliv Transl Res. 2020 Jun;10(3):801-814
pubmed: 31989414
Drug Deliv. 2018 Nov;25(1):132-142
pubmed: 29275642
Int J Pharm. 2017 Sep 15;530(1-2):1-11
pubmed: 28733244
J Clin Microbiol. 2018 Mar 26;56(4):
pubmed: 29367292
Acta Pol Pharm. 2010 Jul-Aug;67(4):327-34
pubmed: 20635527
J Liposome Res. 2015;25(2):107-21
pubmed: 25058447
Drug Deliv Transl Res. 2020 Oct;10(5):1459-1475
pubmed: 32394333
Eur J Pharm Biopharm. 2012 Apr;80(3):585-95
pubmed: 22182528
Int J Pharm. 2013 Aug 16;452(1-2):300-10
pubmed: 23684658
Drug Deliv. 2018 Nov;25(1):12-22
pubmed: 29219628
J Liposome Res. 2018 Sep;28(3):182-192
pubmed: 28480807
Int J Pharm. 2018 Oct 5;549(1-2):249-260
pubmed: 30077759
J Pharm Sci. 1996 Oct;85(10):1017-25
pubmed: 8897265
Adv Drug Deliv Rev. 2013 Aug;65(9):1215-33
pubmed: 23673149
Drug Deliv. 2018 Nov;25(1):938-949
pubmed: 29658325
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):46-55
pubmed: 29024354
J Pharm Sci. 1963 Dec;52:1145-9
pubmed: 14088963
Biomaterials. 2013 Jan;34(4):1018-23
pubmed: 23146429

Auteurs

Diana Aziz (D)

Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.

Sally Mohamed (S)

Faculty of Pharmacy, Department of Microbiology and Immunology, Cairo University, Cairo, Egypt.

Saadia Tayel (S)

Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.

Amal Makhlouf (A)

Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antifongiques › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Maladies de l'oeil › Infections de l'oeil › Mycoses oculaires › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Maladies de l'oeil › Maladies de la cornée › Kératite › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Phénomènes chimiques › Taille de particule › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Phénomènes chimiques › Perméabilité › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › Poloxamère › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Composés chimiques organiques › Rotaxanes › Implementing polymeric pseudorotaxanes for...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Naphtalènes › Tolnaftate › Implementing polymeric pseudorotaxanes for...